SOLICITATION NOTICE
A -- Analysis of 15 samples via in vitro cell culture assay
- Notice Date
- 7/21/2009
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- 1058823
- Archive Date
- 8/20/2009
- Point of Contact
- Jaclyn Stielper, , Doreen Williams ,
- E-Mail Address
-
jaclyn.stielper@fda.hhs.gov, doreen.williams@fda.hhs.gov
(jaclyn.stielper@fda.hhs.gov, doreen.williams@fda.hhs.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6, simplified acquisition procedures and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular 05-30. This announcement constitutes the only 100% small business set aside solicitation and a written solicitation will not be issued. This synopsis, NAICS code 541711, is to notify contractors that the government intends to issue a Firm Fixed Price Purchase Order in accordance with FAR Part 13.106 for the following statement of work, under the simplified acquisition procedures. Any firm that believes it is capable of providing the required service as stated herein may submit a capability statement to document its ability to provide the required services. A determination to compete this procurement based on a response to this notice is solely within the discretion of the Government. The Government reserves the right to award a contract without discussions if the Contracting Officer determines that the initial offer(s) is/are providing the Best Value and discussions are not necessary. Award will be made to the party whose quote offers the best value to the Government, technical, price, and other factors considered. The Government may award this contract to other than the lowest price technically acceptable quote. The Government will evaluate information based on the following evaluation criteria: 1) Technical Capability factor described to "Meet or Exceed the Requirement," 2) Past Performance and 3) Price. Technical Capability and Past Performance, when combined, are significantly more important than price. This solicitation is issued as a Request for Quote (RFQ). The Food and Drug Administration (FDA) intends to award a purchase order for biotechnology research and development services. The Statement of Work is as follows: Performance Work Statement The purpose of the test is to quantify activity of multiple signal transduction pathways in biological samples including mouse skin, liver, muscle, and lungs. Quantification activity of a minimum of 50 transcription factors in a uniform assay is needed to create a comprehensive profile of response of biological tissues to treatment with adjuvants. FDA will provide samples which the Contractor will process using FACTORIAL method, in vitro assay. The Contractor will provide relative activities of 51 transcription factors currently included in their panel. The processing involves nucleic acids isolation, RT-PCR amplification of Factorial plasmids, restriction digestion and electrophoretic identification of the DNA products. Includes experimental setup, production and assembly of endotoxin-free Factorial plasmid library, assaying the tracer luciferase in blood samples, isolation, quantification and assessing the quality of total RNA preparations performing Factorial detection for determining reporter RNAs’ profiles (30 samples in triplicates, total of 90 detection conditions), calculation of the TF activity profiles and statistical assessments of the results. Signals that control genome expression are executed through coordinated changes in the activities of transcription factors (TFs) - proteins that bind gene regulatory elements and modulate transcription. Mammalian genomes encode about 2000 TFs that, according to DNA binding similarities, can be classified into few hundred families. By analyzing activities of multiple TFs one should be able to obtain an informative snapshot of gene regulatory network. However, high-content analysis of TFs requires adequate tools. Assays that make use of reporter gene constructs (e.g., luciferase reporters) can be used to analyze only one or two transcription factors at a time. In contrast, DNA-binding assays can potentially be used to assess multiple transcription factors, but provide limited biological information because DNA binding is only one of many factors in the regulation of transcription factor activity. The Contractor shall conceptualize and developed a simple homogeneous assayenabling assessment of multiple transcription factors’ activities in a single experiment. Location The services are to be performed at the Contractor’s facility. The deliverables are to be sent to 5516 Nicholson Lane Kensington, MD 20895. Period of Performance DOA – September 30, 2009. CCR: Vendors must be registered in the Central Contractor Register (CCR) prior to the award of a contract. You may register by going to www.ccr.gov. You will need your Dun & Bradstreet number and banking information. QUESTIONS DEADLINE: All questions are to be submitted via email to Jaclyn.Stielper@fda.hhs.gov no later than July 31, 2009 at 4:30 PM EST. QUOTATIONS DUE: All quotations are due, via email to: Jaclyn.Stielper@fda.hhs.gov, no later than 4:30 PM EST on August 5, 2009. PROVISIONS and CLAUSES: The provision at FAR 52.212-1, Instructions to Offerors Commercial Items applies to this solicitation. The following agenda has been attached to this provision: None. Offerors shall include a completed copy of the provision at FAR 52.212-3, Offeror Representations and Certifications Commercial Items. The clause at FAR 52.212-4, Contract Terms and Conditions, Commercial Items applies to this acquisition. The following agenda has been attached to the clause: None. The clause at FAR 52.212-5 Contract Terms and Conditions Required to Implement Statues or Executive Orders, Commercial Items applies to this acquisition. The following FAR clauses cited are applicable: FAR 52.217-8, FAR 52.217-9, FAR 52.222-26, FAR 52.222-35, FAR 52.222-36, and FAR 52.232-33. Clauses and provisions are incorporated by reference and apply to this acquisition. Responses to this notice must be sent via email to Jaclyn.Stielper@fda.hhs.gov. Telephone calls will not be accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/1058823/listing.html)
- Place of Performance
- Address: 5516 Nicholson Lane, Kensington, Maryland, 20895, United States
- Zip Code: 20895
- Zip Code: 20895
- Record
- SN01882927-W 20090723/090722002240-9bd5165bdbe417d422e5cbbb4ec094b9 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |